Armata enters ATM offering agreement for up to $100M of common stock

Armata Pharmaceuticals, Inc.

Entered Capital on Demand Sales Agreement with JonesTrading for at-the-market offering of common stock up to $100M.
JonesTrading will earn commission of up to 3.0% of gross proceeds; sales may be made on NYSE American.
Company not obligated to sell; Jones not obligated to buy; program entirely at Company's discretion.
Offered under existing S-3 registration statement (File No. 333-289585) and prospectus supplement dated Dec 1, 2025.
Agreement contains customary representations, warranties, and indemnification; either party may terminate on three days' notice.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Armata Pharmaceuticals, Inc. entered into Capital on DemandTM Sales Agreement with JonesTrading Institutional Services LLC valued at up to $100,000,000 (effective 2025-12-01).

Action: entry
Agreement: atm program
Counterparty: JonesTrading Institutional Services LLC
Value: up to $100,000,000
Effective: 2025-12-01

Exact text from the filing

On December 1, 2025, Armata Pharmaceuticals, Inc. (the “Company”) entered into a Capital on DemandTM Sales Agreement (the “Sales Agreement”) with JonesTrading Institutional Services LLC (“Jones”) with respect to an at the market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share (the “Common Stock”), having an aggregate offering price of up to $100,000,000 (the “Placement Shares”) subject to certain conditions, through Jones as sales agent.

View on SEC.gov

197 material agreements filed in the last 30 days. Browse all material agreements →

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-117387

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.